0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Special Feature |

Picture of the Month—Diagnosis FREE

Arch Pediatr Adolesc Med. 2012;166(3):284. doi:10.1001/archpediatrics.2011.789b.
Text Size: A A A
Published online

DENOUEMENT AND DISCUSSION: A CASE OF NEONATAL LUPUS ERYTHEMATOSUS AND ASSOCIATED HEPATITIS

Based on the cutaneous findings and positive antibodies to Sjögren syndrome antigen A/Ro (SSA/Ro) and Sjögren syndrome antigen B/La (SSB/La), a diagnosis of neonatal lupus erythematosus (NLE) was established. Results of scalp fungal culture were negative. Electrocardiogram (ECG) and echocardiogram were normal. Photoprotection was recommended and use of hydrocortisone ointment, 2.5%, was started twice daily for 2 weeks. The scalp lesions resolved by 6 months of age with no sequelae. No further manifestations of liver insufficiency developed, and hepatic transaminase levels normalized by 8 months of age. The patient's mother had been diagnosed with mixed connective tissue disease 3 years prior, but her antibody status was uncertain.

Neonatal lupus erythematosus is an autoimmune syndrome that may have cutaneous, cardiac, hematologic, and hepatic manifestations.1 The syndrome is acquired by the transplacental passage of antibodies to SSA/Ro and/or SSB/La extractable nuclear antigens. These antibodies are often found in patients with known rheumatic disease, such as systemic lupus erythematosus and Sjögren syndrome.2 However, at the time of birth, between 30% and 66% of mothers of babies with NLE are asymptomatic and without a rheumatologic diagnosis.3 An estimated 2% of babies born to mothers having these antibodies will develop NLE. The risk of having another child with NLE rises to an estimated 25% in mothers who have a previous child with NLE, and therefore, their subsequent pregnancies need to be followed up closely with fetal echocardiography.4

The most common manifestation of NLE is a rash characterized by annular erythematous plaques with scale or central atrophy, located primarily on the scalp and periorbital area.4 The cutaneous lesions may be misdiagnosed as tinea corporis, atopic dermatitis, seborrheic dermatitis, or urticaria.5 The mean age at onset of cutaneous findings is 6 weeks, with about 23% of children having a rash at birth.2 New lesions may develop during the first several months of life, but rarely after 6 months of age. The rash is present for an average of 15 to 17 weeks and usually resolves without scarring.2

The most serious manifestation of NLE, congenital atrioventricular block (CAVB), is irreversible. Ninety to 95% of all cases of CAVB of any degree are attributable to NLE. Prospective studies reveal that 1% to 2% of babies born to mothers with the anti–SSA/Ro antibody have third-degree CAVB.6 Because the CAVB occurs during the in utero development of the fetal atrioventricular node, onset will not occur after birth of the child.3

Other manifestations of NLE include hepatobiliary disease and hematologic abnormalities. Liver involvement is seen in 10% to 26% of patients with NLE and most commonly presents weeks to months after birth with transient liver enzyme elevations, as in this patient. Less common presentations include cholestasis with hyperbilirubinemia or, rarely, acute liver failure.7 Thrombocytopenia may occur in as many 15% of cases, and anemia and neutropenia have been reported.8

If NLE is suspected, evaluation of the infant should include physical examination, ECG, and serologic testing for SSA/Ro and SSA/La antibodies. A complete blood cell count with differential and liver function panels should be considered to evaluate for cytopenia or hepatobiliary involvement. Diagnosis is established by the presence of the characteristic rash and/or congenital heart block and the presence of antibodies to SSA/Ro and/or SSB/La in the infant or mother. Skin biopsy is usually not necessary.1 A normal ECG after birth rules out heart involvement. If antibodies are not present in the child or mother, seek an alternative diagnosis.

Treatment of NLE varies depending on the underlying manifestations. The rash and other noncardiac manifestations are generally self-limited and resolve with the disappearance of maternal antibodies in 6 to 8 months. A combination of parental reassurance, photoprotection (if a rash is present), and observation of the child is most often adequate. Depending on the degree, treatment of CAVB ranges from reassurance to pacemaker placement. Gastroenterology referral should be considered when rapid rises in liver enzyme levels or signs of liver insufficiency are observed. However, serial laboratory monitoring and supportive care are usually adequate. Systemic corticosteroids and other immunosuppressive agents are usually not required.

Return to Quiz Case.

Correspondence: Mark F. Hoeltzel, MD, Section of Rheumatology, Children's Mercy Hospitals, 2401 Gillham Rd, Kansas City, MO 64108 (mfhoeltzel@cmh.edu).

Accepted for Publication: July 23, 2011.

Author Contributions:Study concept and design: Adil and Hoeltzel. Acquisition of data: Horii and Hoeltzel. Drafting of the manuscript: Adil. Critical revision of the manuscript for important intellectual content: Horii and Hoeltzel. Study supervision: Horii and Hoeltzel.

Financial Disclosure: None reported.

Lee LA. Cutaneous lupus in infancy and childhood.  Lupus. 2010;19(9):1112-1117
PubMed   |  Link to Article
Neiman AR, Lee LA, Weston WL, Buyon JP. Cutaneous manifestations of neonatal lupus without heart block.   J Pediatr. 2000;137(5):674-680
PubMed   |  Link to Article
Izmirly PM, Rivera TL, Buyon JP. Neonatal lupus syndromes.  Rheum Dis Clin North Am. 2007;33(2):267-285, vi
PubMed   |  Link to Article
Lee LA. The clinical spectrum of neonatal lupus.  Arch Dermatol Res. 2009;301(1):107-110
PubMed   |  Link to Article
Buyon JP, Lindsley CB, Silverman ED. Neonatal lupus erythematosus. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB, eds. Textbook of Pediatric Rheumatology. 6th ed. Philadelphia, PA: Elsevier Inc; 2011:361-374
Buyon JP, Clancy RM, Friedman DM. Cardiac manifestations of neonatal lupus erythematosus.  Nat Clin Pract Rheumatol. 2009;5(3):139-148
PubMed   |  Link to Article
Lee LA, Sokol RJ, Buyon JP. Hepatobiliary disease in neonatal lupus: prevalence and clinical characteristics in cases enrolled in a national registry.  Pediatrics. 2002;109(1):E11
PubMed   |  Link to Article
Silverman E, Jaeggi E. Non-cardiac manifestations of neonatal lupus erythematosus.  Scand J Immunol. 2010;72(3):223-225
PubMed   |  Link to Article

Figures

Tables

References

Lee LA. Cutaneous lupus in infancy and childhood.  Lupus. 2010;19(9):1112-1117
PubMed   |  Link to Article
Neiman AR, Lee LA, Weston WL, Buyon JP. Cutaneous manifestations of neonatal lupus without heart block.   J Pediatr. 2000;137(5):674-680
PubMed   |  Link to Article
Izmirly PM, Rivera TL, Buyon JP. Neonatal lupus syndromes.  Rheum Dis Clin North Am. 2007;33(2):267-285, vi
PubMed   |  Link to Article
Lee LA. The clinical spectrum of neonatal lupus.  Arch Dermatol Res. 2009;301(1):107-110
PubMed   |  Link to Article
Buyon JP, Lindsley CB, Silverman ED. Neonatal lupus erythematosus. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB, eds. Textbook of Pediatric Rheumatology. 6th ed. Philadelphia, PA: Elsevier Inc; 2011:361-374
Buyon JP, Clancy RM, Friedman DM. Cardiac manifestations of neonatal lupus erythematosus.  Nat Clin Pract Rheumatol. 2009;5(3):139-148
PubMed   |  Link to Article
Lee LA, Sokol RJ, Buyon JP. Hepatobiliary disease in neonatal lupus: prevalence and clinical characteristics in cases enrolled in a national registry.  Pediatrics. 2002;109(1):E11
PubMed   |  Link to Article
Silverman E, Jaeggi E. Non-cardiac manifestations of neonatal lupus erythematosus.  Scand J Immunol. 2010;72(3):223-225
PubMed   |  Link to Article

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections